In neurogenic shock, what is the relative benefit of epinephrine (adrenaline) compared with norepinephrine (noradrenaline) as a vasopressor?

Norepinephrine is Superior to Epinephrine in Neurogenic Shock

Norepinephrine should be the first-line vasopressor for neurogenic shock, with epinephrine reserved only as a second-line agent when norepinephrine alone fails to maintain adequate blood pressure. This recommendation is based on established sepsis guidelines that apply to all forms of distributive shock, including neurogenic shock, and is supported by evidence showing epinephrine's association with higher mortality and adverse metabolic effects 1, 2.

Guideline-Based Vasopressor Selection

First-Line Agent: Norepinephrine

• Norepinephrine is recommended as the first-choice vasopressor for all distributive shock states, including neurogenic shock (grade 1B recommendation) 1.
• The Surviving Sepsis Campaign explicitly states norepinephrine should be used as the initial vasopressor to target a mean arterial pressure (MAP) of 65 mmHg 1.
• For distributive shock of any etiology, norepinephrine is the preferred initial agent with strong recommendation strength 2.

Dosing Strategy for Norepinephrine

• Start norepinephrine at 0.1–0.5 µg/kg/min (approximately 7–35 µg/min for a 70-kg adult) 2.
• Titrate to achieve MAP ≥ 65 mmHg 1, 2.
• Continue escalating up to 0.5 µg/kg/min before adding a second-line agent 2.

When to Add Epinephrine (Second-Line Only)

Escalation Threshold

• Add epinephrine only when norepinephrine reaches 0.25–0.50 µg/kg/min and MAP remains < 65 mmHg (grade 2B recommendation) 1, 2.
• Epinephrine should be "added to and potentially substituted for norepinephrine" when an additional agent is needed 1.
• The guideline-endorsed escalation sequence is: norepinephrine first → add vasopressin or epinephrine second → never use epinephrine as monotherapy 2.

Epinephrine Dosing

• When added, start epinephrine at 0.1–0.5 µg/kg/min and titrate to effect 2.
• The FDA label indicates epinephrine infusion rates of 0.05–2 µg/kg/min for septic shock 3.

Evidence Against Using Epinephrine as First-Line

Mortality and Safety Concerns

The most recent and highest-quality evidence demonstrates significant harm with epinephrine compared to norepinephrine:

• In post-cardiac arrest shock (another form of distributive shock), epinephrine was associated with significantly higher all-cause hospital mortality (adjusted OR 2.6; 95% CI 1.4–4.7; P = 0.002) and cardiovascular mortality (adjusted OR 5.5; 95% CI 3.0–10.3; P < 0.001) compared to norepinephrine 4.
• This 2022 multicenter study of 766 patients showed consistent results across multiple sensitivity analyses and propensity-score matching 4.

Refractory Shock Risk

• In cardiogenic shock after myocardial infarction, epinephrine caused a significantly higher incidence of refractory shock (37% vs. 7%; P = 0.008) compared to norepinephrine, leading to early trial termination 5.
• This finding is particularly relevant because neurogenic shock shares hemodynamic features with other distributive states where cardiac output may be relatively preserved but vascular tone is lost 5.

Adverse Metabolic and Hemodynamic Effects

• Epinephrine causes significant tachycardia, lactic acidosis, and increased myocardial oxygen demand compared to norepinephrine 5, 6.
• In cardiogenic shock, epinephrine increased heart rate significantly from H2 to H24 while norepinephrine did not (P < 0.0001) 5.
• Epinephrine was associated with worsening lactate levels and inadequate splanchnic perfusion (increased tonometered PCO₂ gap, P < 0.01), whereas norepinephrine improved these parameters 6.
• Epinephrine increased cardiac double product (a marker of myocardial oxygen consumption) significantly more than norepinephrine (P = 0.0002) 5.

Clinical Algorithm for Neurogenic Shock

Step 1: Initial Resuscitation

• Ensure adequate fluid resuscitation first; administer at least 30 mL/kg of crystalloid before initiating vasopressors 2.
• In neurogenic shock, be cautious with excessive fluids due to risk of pulmonary edema from loss of sympathetic tone 1.

Step 2: Initiate Norepinephrine

• Start norepinephrine at 0.1–0.5 µg/kg/min 2.
• Target MAP ≥ 65 mmHg 1, 2.
• Place an arterial catheter for continuous blood pressure monitoring 1, 2.

Step 3: Escalate Norepinephrine

• Titrate norepinephrine up to 0.5 µg/kg/min (approximately 35 µg/min in a 70-kg adult) 2.
• Monitor for adequate tissue perfusion: urine output ≥ 0.5 mL/kg/hr, decreasing lactate, normal mentation, warm extremities 7.

Step 4: Add Second-Line Agent (If Needed)

• Preferred second-line: Add vasopressin 0.03 U/min (fixed dose, non-titrated) when norepinephrine reaches 0.25–0.50 µg/kg/min and MAP < 65 mmHg 2.
• Alternative second-line: Add epinephrine 0.1–0.5 µg/kg/min if vasopressin is unavailable or contraindicated 2.

Step 5: Consider Bradycardia Management

• In neurogenic shock with significant bradycardia (HR < 60 bpm), atropine or pacing may be needed in addition to vasopressors 2.
• Do not use dopamine for bradycardia in neurogenic shock; it increases arrhythmia risk and mortality compared to norepinephrine 1, 2.

Common Pitfalls and How to Avoid Them

Pitfall 1: Using Epinephrine First-Line

• Never start with epinephrine in neurogenic shock; the evidence shows higher mortality, refractory shock, and metabolic derangements 4, 5.
• Epinephrine's β-adrenergic effects cause tachycardia and increased myocardial oxygen demand without improving outcomes 5, 6.

Pitfall 2: Inadequate Fluid Resuscitation

• Do not start vasopressors before ensuring adequate volume status; norepinephrine in hypovolemia worsens tissue perfusion despite raising blood pressure 2.
• However, in neurogenic shock, avoid excessive fluids that may cause pulmonary edema 1.

Pitfall 3: Using Dopamine for "Renal Protection"

• Low-dose dopamine (2–5 µg/kg/min) has no proven benefit for renal protection (grade 1A recommendation) and delays appropriate therapy 1, 2.
• Norepinephrine actually improves renal blood flow in distributive shock 2.

Pitfall 4: Monitoring MAP Alone

• Always combine MAP targets with tissue perfusion markers: lactate clearance, urine output, mental status, capillary refill, skin temperature 7.
• A "normal" MAP with rising lactate or falling urine output indicates inadequate perfusion 7.

Pitfall 5: Delaying Arterial Line Placement

• All patients requiring vasopressors should have an arterial catheter placed as soon as practical for continuous monitoring and rapid titration 1, 2.

Special Considerations in Neurogenic Shock

Bradycardia Management

• Neurogenic shock often presents with bradycardia due to loss of sympathetic tone 2.
• Atropine 0.5–1 mg IV may be needed for symptomatic bradycardia 2.
• Transcutaneous or transvenous pacing should be considered if bradycardia persists 2.
• Norepinephrine does not reliably increase heart rate because vagal reflexes offset its β-adrenergic effects 2.

Avoiding Excessive Vasopressor Doses

• If MAP remains < 65 mmHg despite norepinephrine 0.5 µg/kg/min plus vasopressin 0.03 U/min, reassess volume status and consider other causes of shock 2.
• Adding epinephrine at this point carries significant risk of refractory shock and metabolic complications 5.

Why Epinephrine Should Not Be First-Line

The convergence of guideline recommendations and recent high-quality evidence makes the choice clear:

• Guidelines explicitly recommend norepinephrine first for all distributive shock 1, 2.
• The most recent comparative study (2022,766 patients) showed doubled mortality with epinephrine in post-cardiac arrest distributive shock 4.
• A randomized trial in cardiogenic shock (2018) was terminated early due to 5-fold higher refractory shock rates with epinephrine 5.
• Epinephrine causes harmful metabolic effects: lactic acidosis, splanchnic hypoperfusion, increased myocardial oxygen demand, and tachyarrhythmias 5, 6.

Until definitive randomized trials in neurogenic shock specifically are conducted, the weight of evidence from other distributive shock states and guideline consensus strongly favors norepinephrine as first-line therapy, with epinephrine reserved only for refractory cases 1, 2, 4.